PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis.
Moyo TK, Kishtagari A, Villaume MT, McMahon B, Mohan SR, Stopczynski T, Chen SC, Fan R, Huo Y, Moon H, Tang Y, Bejan CA, Childress M, Anderson I, Rawling K, Simons RM, Moncrief A, Caza R, Dugger L, Collins A, Dudley CV, Ferrell PB, Byrne M, Strickland SA, Ayers GD, Landman BA, Mason EF, Mesa RA, Palmer JM, Michaelis LC, Savona MR.
Moyo TK, et al. Among authors: villaume mt.
Clin Cancer Res. 2023 Jul 5;29(13):2375-2384. doi: 10.1158/1078-0432.CCR-22-3192.
Clin Cancer Res. 2023.
PMID: 37036505
Clinical Trial.